Skip to main content
Michael Curi, MD, Vascular Surgery, Jersey City, NJ, Trinitas Regional Medical Center

MichaelA.CuriMDMPA

Vascular Surgery Jersey City, NJ

Chief, Vascular Surgery Rutgers-New Jersey Medical School

Dr. Curi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Curi's full profile

Already have an account?

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumFellowship, Vascular Surgery, 2005 - 2006
  • University of Chicago
    University of ChicagoResidency, Surgery, 1998 - 2005
  • Rutgers New Jersey Medical School
    Rutgers New Jersey Medical SchoolClass of 1998

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2018 - 2023
  • NJ State Medical License
    NJ State Medical License 2010 - 2023
  • MD State Medical License
    MD State Medical License 2006 - 2010
  • IL State Medical License
    IL State Medical License 1998 - 2005
  • American Board of Surgery Vascular Surgery

Awards, Honors, & Recognition

  • Fellow American College of Surgeons

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Basilic Vein Superficialization Is an Effective Alternative to Transposition in Patients Requiring Brachiobasilic Arteriovenous Fistula  
    Joe T Huang, Frank T Padberg, Michael A Curi, Journal of Vascular Surgery

Authored Content

  • Basilic Vein Superficialization Is an Effective Alternative to Transposition in Patients Requiring Brachiobasilic Arteriovenous FistulaJuly 2018

Press Mentions

  • Humacyte Launches Phase II Vascular Trauma Humacyl Vessel Trial
    Humacyte Launches Phase II Vascular Trauma Humacyl Vessel TrialOctober 26th, 2018
  • Humacyte Commences Phase II Vascular Trauma Trial
    Humacyte Commences Phase II Vascular Trauma TrialOctober 26th, 2018
  • Humacyte Highlights Robust Expanded Access Program and Patient Testimonial for Human Acellular Vessels
    Humacyte Highlights Robust Expanded Access Program and Patient Testimonial for Human Acellular VesselsAugust 20th, 2021

Professional Memberships

Hospital Affiliations